In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016
| Autor: | Michael Dicay, Giuseppe Cirino, Piero Del Soldato, John L. Wallace, Marcelo Nicolas Muscará, Webb McKnight |
|---|---|
| Přispěvatelé: | J. L., Wallace, M. N., Muscara, W., Mcknight, M., Dicay, P. D., Soldato, Cirino, Giuseppe |
| Jazyk: | angličtina |
| Rok vydání: | 1999 |
| Předmět: |
Male
Nitroprusside Thromboxane Stereochemistry Drug Evaluation Preclinical Pharmacology Inhibitory postsynaptic potential Nitric Oxide Drug Drug Evaluation Nitric oxide chemistry.chemical_compound therapeutic use Rats Rat Fibrinolytic Agents In vivo Oral administration Antithrombotic Medicine Animals Preclinical Fibrinolytic Agent Platelet Rats Wistar therapeutic use Platelet Aggregation Inhibitor Animals Aspirin metabolism Nitroprusside Aspirin Dose-Response Relationship Drug business.industry Thromboxanes Hematology humanities Rats chemistry Mechanism of action therapeutic use Male Nitric Oxide medicine.symptom biosynthesis business analogs /&/ derivatives/therapeutic use Dose-Response Relationship Platelet Aggregation Inhibitors Wistar Thromboxane |
| Popis: | In summary, these results demonstrate that NCX-4016 can inhibit thrombus formation in an in vivo model. This effect is most likely due to nitric oxide release from the compound, but may also be dependent, to some extent, on suppression of thromboxane synthesis. It is possible that in certain circumstances, a dual mechanism of action in inhibiting platelet aggregation, together with the documented ability of NCX-4016 to inhibit neutrophil adherence, could offer distinct advantages over agents that only inhibit platelet aggregation through a single mechanism. The marked increase in gastric tolerability of NCX-4016 over that of aspirin also represents an attractive feature of this compound as a prophylactic therapy for thrombotic disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|